查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1833636

产前及新生儿基因检测市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

Prenatal and Newborn Genetic Testing Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 145 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年全球产前和新生儿基因检测市场价值为 81 亿美元，预计到 2034 年将以 12.8% 的复合年增长率增长至 91 亿美元。

产前和新生儿基因检测市场 - IMG1

唐氏症、囊性纤维化和脊髓性肌肉萎缩症等遗传疾病的盛行率日益上升，推动了透过产前和新生儿基因检测进行早期发现的需求。越来越多的准父母寻求保障和早期介入方案。

市场范围
起始年份 2024
预测年份 2025-2034
起始值 81亿美元
预测值 91亿美元
复合年增长率 12.8%

试剂盒与试剂应用日益普及

试剂盒和试剂细分市场在2024年占据了相当大的份额，因为这些耗材对于临床诊断和研究工作流程都至关重要。实验室和诊断中心依赖高品质、可靠的试剂来确保结果的准确性和可重复性。随着早期基因筛检需求的不断成长，检测量不断成长，耗材的重复使用特性将持续提升细分市场的绩效。

产前检查需求不断增加

由于产妇年龄增长、风险意识增强以及临床上大力推广非侵入性和侵入性检测，产前检测领域在2024年占据了相当大的份额。这些检测有助于在怀孕早期检测出染色体异常、基因突变和胎儿畸形，有助于临床上做出更明智的决策。孕早期筛检的兴起以及基因检测范围的扩大推动了该领域的持续成长。

cfDNA 获得关注

2024 年，无细胞 DNA (cfDNA) 检测领域将占据可持续的份额，这得益于一种用于筛检 21、18 和 13 三体等常见染色体疾病的非侵入性、高度准确的方法。此方法可分析母体血液中循环的胎儿 DNA 片段，从而减少了对羊膜穿刺等侵入性手术的需求。

北美将成为推动力地区

由于强大的医疗基础设施、先进的实验室能力以及广泛的基因检测服务，北美产前和新生儿基因检测市场预计将在2024年实现大幅成长。在美国和加拿大，早期筛检已被广泛采用，这得益于良好的保险覆盖范围、监管支持以及公众意识的不断提升。基因组医学的持续投入、NIPT指南的扩展以及基于人工智慧的诊断工具的整合，将进一步推动该地区市场的成长。

产前和新生儿基因检测市场的主要参与者有 Genes2me、Trivitron Healthcare、Retrogen、Aetna、Fulgent Genetics、Eurofins、Illumina、CENTOGENE、Genelab (Clevergene)、Thermo Fisher Scientific、Myriad Genetics、Nateras、Revvity、LaCARCAR、BGI Group、Billion Scientific、Myriad Genetics、Naterd、Labvity、LaCAR

为了巩固其在产前和新生儿基因检测市场的地位，各公司正在推行创新驱动和扩张导向的混合策略。许多公司正在投资研发，以开发高通量平台，并扩大其检测组合，以涵盖罕见遗传疾病和遗传性疾病。与医院、学术机构和技术合作伙伴的策略合作，使其能够更快地渗透市场，并涵盖多样化的患者群体。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

  • 产业生态系统分析
    • 供应商格局
    • 每个阶段的增值
    • 影响价值链的因素
  • 产业衝击力
    • 成长动力
      • 产妇年龄上升，产前筛检需求增加
      • NIPT 检测需求不断成长
      • 遗传疾病发生率上升
      • 父母对早期诊断的认识与需求不断增强
      • 不断改进技术，提高准确性和可近性
    • 产业陷阱与挑战
      • 高级测试成本高昂
      • 资料隐私和安全
    • 市场机会
      • 产前护理中个人化医疗的需求日益增长
      • 新兴市场的渗透率不断提高
      • 扩大公私合作倡议
  • 成长潜力分析
  • 监管格局
    • 北美洲
    • 欧洲
    • 亚太地区
  • 基因检测产业的投资与融资格局
  • 技术格局
    • 新兴技术
    • 现有技术
  • 未来市场趋势
  • 波特的分析
  • PESTEL分析

第四章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 公司市占率分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 关键进展
    • 併购
    • 伙伴关係与协作
    • 新产品发布
    • 扩张计划

第五章：市场估计与预测：按产品和服务，2021 - 2034 年

  • 主要趋势
  • 试剂盒和试剂
  • 服务

第六章：市场估计与预测：按测试类型，2021 - 2034 年

  • 主要趋势
  • 产前检查
    • 筛检
      • 非侵入性产前检测（NIPT）
      • 携带者筛检
      • 血清筛检
      • 颈部透明带超音波检查
    • 诊断
      • 绒毛膜绒毛取样（CVS）
      • 羊膜穿刺术
  • 新生儿检查
    • 足跟采血检查
    • 听力筛检
    • 严重先天性心臟缺陷（CCHD）
    • 其他新生儿检测类型

第七章：市场估计与预测：按技术分类，2021 - 2034 年

  • 主要趋势
  • 下一代定序（NGS）
  • 游离DNA（cfDNA）
  • 阵列比较基因组杂交（aCGH）
  • 萤光原位杂交（FISH）
  • 光谱法
  • 全外显子定序（WES）
  • 其他技术

第 8 章：市场估计与预测：按应用，2021 - 2034 年

  • 主要趋势
  • 唐氏综合症
  • 苯酮尿症（PKU）
  • 囊性纤维化（CF）
  • 镰状细胞性贫血
  • 先天性甲状腺功能低下症
  • Pendred症候群
  • 其他应用

第九章：市场估计与预测：依最终用途，2021 - 2034

  • 主要趋势
  • 医院
  • 诊断实验室
  • 产科和专科诊所
  • 其他最终用途

第 10 章：市场估计与预测：按地区，2021 年至 2034 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：公司简介

  • Aetna
  • Agilent
  • BGI Group
  • BilliontoOne
  • CENTOGENE
  • Eurofins
  • Fulgent Genetics
  • Genelab (Clevergene)
  • Genes2me
  • Illumina
  • Labcorp
  • LaCAR
  • Myriad Genetics
  • Natera
  • Retrogen
  • Revvity
  • Thermo Fisher Scientific
  • Trivitron Healthcare
  • Yourgene Health
简介目录
Product Code: 1906

The Global Prenatal and Newborn Genetic Testing Market was valued at USD 8.1 billion in 2024 and is estimated to grow at a CAGR of 12.8% to reach USD 9.1 billion by 2034.

Prenatal and Newborn Genetic Testing Market - IMG1

The increasing prevalence of genetic conditions such as Down syndrome, cystic fibrosis, and spinal muscular atrophy is driving demand for early detection through prenatal and newborn genetic testing. Expectant parents are increasingly seeking reassurance and early intervention options.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$8.1 Billion
Forecast Value$9.1 Billion
CAGR12.8%

Rising Adoption of Kits and Reagents Segment

The kits and reagents segment held a significant share in 2024, as these consumables are essential for both clinical diagnostics and research workflows. Laboratories and diagnostic centers depend on high-quality, reliable reagents to ensure accurate and reproducible results. As testing volumes grow, driven by increasing demand for early genetic screening, the recurring nature of consumable use continues to boost segment performance.

Increasing Demand for the Prenatal Tests Segment

The prenatal tests segment held a sizeable share in 2024, owing to rising maternal age, increased risk awareness, and strong clinical adoption of non-invasive and invasive testing options. These tests help detect chromosomal abnormalities, genetic mutations, and fetal anomalies early in pregnancy, enabling more informed clinical decision-making. The shift toward first-trimester screening and the inclusion of expanded genetic panels have fueled sustained growth in this segment.

cfDNA to Gain Traction

The cell-free DNA (cfDNA) testing segment held a sustainable share in 2024, driven by a non-invasive, highly accurate method to screen for common chromosomal conditions like trisomy 21, 18, and 13. This method analyzes fetal DNA fragments circulating in maternal blood, reducing the need for invasive procedures like amniocentesis.

North America to Emerge as a Propelling Region

North America prenatal and newborn genetic testing market is poised to grow at a sizeable share in 2024, driven by strong healthcare infrastructure, advanced lab capabilities, and widespread access to genetic services. In the U.S. and Canada, early screening is widely adopted, supported by favorable insurance coverage, regulatory backing, and increasing public awareness. Continued investment in genomic medicine, expansion of NIPT guidelines, and integration of AI-based diagnostic tools are further fueling market growth across this region.

Major players in the prenatal and newborn genetic testing market are Genes2me, Trivitron Healthcare, Retrogen, Aetna, Fulgent Genetics, Eurofins, Illumina, CENTOGENE, Genelab (Clevergene), Thermo Fisher Scientific, Myriad Genetics, Natera, Revvity, LaCAR, BGI Group, BillionToOne, LabCorp, Agilent, and Yourgene Health.

To strengthen their position in the prenatal and newborn genetic testing market, companies are pursuing a mix of innovation-driven and expansion-focused strategies. Many are investing in R&D to develop high-throughput platforms and broaden their test portfolios to cover rare genetic conditions and inherited disorders. Strategic collaborations with hospitals, academic institutions, and technology partners are enabling faster market penetration and access to diverse patient populations.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Product and services trends
    • 2.2.3 Test type trends
    • 2.2.4 Technology trends
    • 2.2.5 Application trends
    • 2.2.6 End use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
    • 3.1.1 Supplier landscape
    • 3.1.2 Value addition at each stage
    • 3.1.3 Factors affecting the value chain
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising maternal age and increasing demand for prenatal screening
      • 3.2.1.2 Increasing demand for NIPT testing
      • 3.2.1.3 Rising incidence of genetic disorders
      • 3.2.1.4 Growing parental awareness and demand for early diagnosis
      • 3.2.1.5 Expanding advancement in technologies for accuracy and accessibility
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of advanced tests
      • 3.2.2.2 Data privacy and security
    • 3.2.3 Market opportunities
      • 3.2.3.1 Growing demand for personalized medicine in prenatal care
      • 3.2.3.2 Increasing penetration in emerging markets
      • 3.2.3.3 Expanding public-private initiatives
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Investment and funding landscape in the genetic testing industry
  • 3.6 Technological landscape
    • 3.6.1 Emerging technologies
    • 3.6.2 Current technologies
  • 3.7 Future market trends
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Merger and acquisition
    • 4.6.2 Partnership and collaboration
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product and Services, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Kits and reagents
  • 5.3 Services

Chapter 6 Market Estimates and Forecast, By Test Type, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Prenatal tests
    • 6.2.1 Screening
      • 6.2.1.1 Non-invasive prenatal testing (NIPT)
      • 6.2.1.2 Carrier screening
      • 6.2.1.3 Serum screening
      • 6.2.1.4 Nuchal translucency ultrasound
    • 6.2.2 Diagnostic
      • 6.2.2.1 Chorionic villus sampling (CVS)
      • 6.2.2.2 Amniocentesis
  • 6.3 Newborn tests
    • 6.3.1 Heel prick test
    • 6.3.2 Hearing screening
    • 6.3.3 Critical congenital heart defect (CCHD)
    • 6.3.4 Other newborn test types

Chapter 7 Market Estimates and Forecast, By Technology, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Next-generation sequencing (NGS)
  • 7.3 Cell-free DNA (cfDNA)
  • 7.4 Array-comparative genomic hybridization (aCGH)
  • 7.5 Fluorescence in-situ hybridization (FISH)
  • 7.6 Spectrometry
  • 7.7 Whole exome sequencing (WES)
  • 7.8 Other technologies

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Down syndrome
  • 8.3 Phenylketonuria (PKU)
  • 8.4 Cystic fibrosis (CF)
  • 8.5 Sickle cell anemia
  • 8.6 Congenital hypothyroidism
  • 8.7 Pendred syndrome
  • 8.8 Other applications

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 Hospitals
  • 9.3 Diagnostic laboratories
  • 9.4 Maternity and specialty clinics
  • 9.5 Other end use

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Italy
    • 10.3.5 Spain
    • 10.3.6 Netherlands
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Argentina
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 UAE

Chapter 11 Company Profiles

  • 11.1 Aetna
  • 11.2 Agilent
  • 11.3 BGI Group
  • 11.4 BilliontoOne
  • 11.5 CENTOGENE
  • 11.6 Eurofins
  • 11.7 Fulgent Genetics
  • 11.8 Genelab (Clevergene)
  • 11.9 Genes2me
  • 11.10 Illumina
  • 11.11 Labcorp
  • 11.12 LaCAR
  • 11.13 Myriad Genetics
  • 11.14 Natera
  • 11.15 Retrogen
  • 11.16 Revvity
  • 11.17 Thermo Fisher Scientific
  • 11.18 Trivitron Healthcare
  • 11.19 Yourgene Health